Here are relevant reports on : breast-cancer-diagnostics-market

• Noninvasive Cancer Diagnostics Market by Instruments (Solid Tumor, Blood Cancer, Lung Cancer, Breast Cancer), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics) - Analysis & Global Forecast to 2019

  The global non-invasive cancer diagnostic market is expected to show considerable growth during the forecast period. This is attributed to growing cancer cases worldwide, especially breast and lung cancer. In 2013, in the U.S. there were more than 1,660,290 new cases of all type of cancers diagnosed in 2013 (American Cancer Society). Increased healthcare expenditure and increase research and development activities are some of the other factors driving the growth of this market. However factors such as high cost of treatment, and stringent regulatory guidelines are limiting the market growth.

  • Published: November 2026
  • Price: $ 4950
  • TOC Available:

• Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2032

  The global cancer biomarkers market is projected to reach USD 54.48 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2026–2032). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.

  • Published: May 2026
  • Price: $ 7150
  • TOC Available:

• Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2030

  The global Tissue Diagnostics market, valued at USD 6.19 billion in 2024, stood at USD 6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of USD10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics.

  • Published: February 2026
  • Price: $ 4950
  • TOC Available:

• Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031

  The global cancer diagnostics market is projected to reach USD 44.92 billion by 2031, growing at a CAGR of 7.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.

  • Published: August 2026
  • Price: $ 4950
  • TOC Available:

• Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031

  The global companion diagnostics market is projected to reach USD 11.57 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.

  • Published: June 2026
  • Price: $ 4950
  • TOC Available:

• Immuno Oncology Assays Market Size, Share & Trends by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026

  The size of global immuno oncology assays market in terms of revenue was estimated to be worth USD 4.4 billion in 2021 and is poised to reach USD 7.9 billion by 2026, growing at a CAGR of 12.5% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

  • Published: April 2021
  • Price: $ 4950
  • TOC Available:

• Cancer Supportive Care Drugs Market by Drug Class (G-CSFS, ESAS, Antiemetics, Bisphosphonates, Opioids, Nsaids), Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers) - Global Forecast to 2023

  Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments. Such factors are expected to drive the cancer supportive care drugs market. However, there are some side effects associated with cancer supportive care drugs which may hinder the market growth.

  • Published: November 2026
  • Price: $ 4950
  • TOC Available:

• Global Breast Cancer Drugs Market

  There are about one million new cases of breast cancer every year. Breast cancer accounts for about 10% of world wide cancer. There has been significant increase in awareness levels with respect to impact on survival rates incase of early diagnosis. Therefore, opening novel opportunities for breast cancer drugs market.

  • Published: November 2026
  • Price: $ 4950
  • TOC Available:

• Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

  The global cancer immunotherapy market size is projected to grow at a CAGR of 14.0%. Market growth can be attributed to the increasing incidence of cancer, rising demand for therapies with minimal adverse effects, increase in adoption of immunotherapy over other treatment options, and enhanced drug development process. However, stringent regulatory policies and the highly consolidated market which may create an obstacle for the entry of small players are the major factors restraining the growth of this market.

  • Published: September 2016
  • Price: $ 4950
  • TOC Available:

• Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035

  The global Next-generation drug conjugates (NDCs) market is projected to reach USD 42.55 billion by 2035, growing at a CAGR of 11.7% during the forecast period (2026–2035). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.

  • Published: April 2026
  • Price: $ 4950
  • TOC Available:

• NEXT
• LAST

Records 1 to 10 of 50